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Abstract
The transition to a value-based payment system offers pathologists the opportunity to play an increased role in population health
by improving outcomes and safety as well as reducing costs. Although laboratory testing itself accounts for a small portion of
health-care spending, laboratory data have significant downstream effects in patient management as well as diagnosis. Pathologists
currently are heavily engaged in precision medicine, use of laboratory and pathology test results (including autopsy data) to reduce
diagnostic errors, and play leading roles in diagnostic management teams. Additionally, pathologists can use aggregate laboratory
data to monitor the health of populations and improve health-care outcomes for both individual patients and populations. For the
profession to thrive, pathologists will need to focus on extending their roles outside the laboratory beyond the traditional role in
the analytic phase of testing. This should include leadership in ensuring correct ordering and interpretation of laboratory testing
and leadership in population health programs. Pathologists in training will need to learn key concepts in informatics and data
analytics, health-care economics, public health, implementation science, and health systems science. While these changes may
reduce reimbursement for the traditional activities of pathologists, new opportunities arise for value creation and new compensation models. This report reviews these opportunities for pathologist leadership in utilization management, precision
medicine, reducing diagnostic errors, and improving health-care outcomes.
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The Opportunities for Pathology
and Pathologists
Expenditures for health care in the United States were approximately $3.65 trillion in 2018, an increase of 4.4% over the
prior year, and are projected to rise from 17.9% of gross domestic product in 2017 to 19.4% in 2027 if current trends continue.1
Health-care spending also rose 4.8% in 2016 and 5.8% in 2017,
well above the inflation rate, which currently is 1.6%. Absent
substantive changes in the efficiency of delivering American
health care, this trend is expected to accelerate due to aging of
the baby boom generation and the corresponding increase in
utilization of medical services.1 Clearly, such a trend would be
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Figure 2. The estimated proportion of 2017 US health-care costs
influenced by laboratory tests when compared to those not influenced
by laboratory testing.

Figure 1. The estimated proportion of laboratory test costs when
compared to all other US health-care costs in 2017 (US$).

unsustainable, as it would result in an ever-increasing taxpayer
burden for government subsidies.2 Moreover, an increasing gap
between demand and capacity without increased resources and
efficiency would ultimately result in poorer outcomes and
diminished access to needed care.
In vitro laboratory tests have been estimated to account for
only 2.3% of total health-care dollars3 or around $82.7 billion
in 2017 (Figure 1). Laboratory testing may increase with the
expansion of value-based reimbursement and precision medicine but will likely remain a small part of overall health-care
expenses, especially as new and expensive therapies are implemented. However, while laboratory tests are a small portion of
health-care expenditures, 94% of objective and structured data
in the electronic medical record (EMR) are from the clinical
laboratory.4 Moreover, some reports suggest that 70% of all
medical decisions are based on laboratory testing.5
A recent literature review, with physician specialist interviews and an Internet-based multiple choice survey, estimated
that an average of 74% of cardiology and oncology patients in
the United States had laboratory tests, which influenced an
average of 64% of medical decisions.3 Laboratory tests were
most often used for initial diagnosis, followed by treatment and
posttreatment monitoring. A report published in 2017 found
that 35% of 72 196 patient encounters studied had laboratory
testing.6 However, this varied substantially: Almost all inpatients (98%) had 1 or more laboratory tests, compared to 56% of
emergency clinic patients and 29% of outpatients.6 A different
perspective is that laboratory testing approaches 100% for
patients being evaluated and managed for infectious diseases,
genetic disorders, neoplastic diseases, myocardial infarction,
therapeutic drug monitoring, and other conditions,7 with the
World Health Organization citing 58 essential diagnostic tests
for diagnosis and treatment of human disease.8
Considering base hospital and physician costs for 2017
(approximately $1.85 trillion) and using 64% as the rate of
influence on treatment decisions, laboratory tests influence
approximately $1.18 trillion of health-care spending (Figure 2).
These “downstream effects” of laboratory tests on clinical
management include choices of medical procedures and

therapy as well as the ordering of additional diagnostic tests,
especially in domains other than the laboratory.
With diagnostic activities in anatomic and clinical pathology/laboratory medicine as the largest part of their medical
specialty, pathologists can significantly impact value-based
care and population health by reducing costs and improving
the quality of patient care.9,10 While increasing the speed and
accuracy of providing a diagnosis has been a historic goal of
pathologists, greater emphasis should be placed on optimizing
the ability of a provider and/or patient to initiate appropriate
intervention in a timely fashion. It is well understood that earlier intervention improves outcomes and reduces costs. For
example, the engagement of a pathologist who discusses biopsy
findings proactively with the treating clinician can reduce days
of unnecessary waiting for a report to initiate treatment as well
as increase the chances of choosing an effective treatment.
Without effective engagement from experts in anatomic and
clinical pathology/laboratory medicine, the converse is also
true: Unnecessary delays and errors in interpretation clearly
lead to poorer clinical outcomes and increased costs.11
Historically, the quality improvement role of pathologists has
been in the analytic phase of laboratory testing.12 The ongoing
pivot to a value-based health-care payment system has resulted
in an increased effort by pathologists to improve appropriate test
ordering (the “pre–pre” analytic phase) and test interpretation
(the “post–post” analytic phase).13 Published examples of interventions illustrate the diversity of opportunities available: pre–
pre analytic utilization management (including decision supports) to address the long-standing “culture of ordering” that
leads to the costs and safety hazards associated with overutilization14-16 and decreasing post–post analytic phase misinterpretation of test results to reduce diagnostic errors. By embracing
these roles, pathologists can decrease health-care costs and
improve quality, thus creating value for health-care systems.17
Pathologists have been actively involved in many areas critical to the implementation of population health and valuebased health care. Four such areas where pathologists have the
opportunity to assume an even greater role and provide leadership include utilization management, precision medicine,
reducing diagnostic errors, and improving health-care outcomes. Pathologists should seize the opportunity to improve
health-care value in these domains. In addition to improving
public health, the role for pathologists in population health and
value-based care is essential for the profession to grow and
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thrive, particularly as reimbursement shifts away from traditional models to reward improved outcomes and efficiency.

Utilization Management
Clinical Scenario
A 45-year-old male patient arrives at the emergency department with a chief complaint of chest pain. The patient is
slightly overweight and does not exercise. He has no other risk
factors for coronary artery disease. An electrocardiogram is
within normal limits. Blood is drawn in this hospital for creatine kinase (CK) and creatine kinase-MB (CKMB) (MB index)
and troponin I. Although troponin values are negative, CK and
CKMB are elevated, the patient is admitted for observation.
Follow-up does not demonstrate evidence of a myocardial
infarct (MI) or any evidence of myocardial ischemia.
Although the accepted standard for exclusion of an MI is a
normal value for troponin, the use of redundant cardiac markers
is still prevalent in the United States. Physicians often argue
that the tests are inexpensive; unfortunately, they fail to consider that the cascade of decisions based upon unnecessary tests
can be significant. Consider the cost of a prolonged emergency
department visit and an unnecessary admission for thousands
of patients across the country as well. The cost of the admission
and further diagnostic workup not only contribute to national
health-care expenditures but also to individual patients’ out-ofpocket costs as well as time off work and other social costs.
There are significant emotional costs of fear, anxiety, and concern to patients, families, and friends during periods of diagnostic and therapeutic uncertainty, as well as significant health
risks for the patient when invasive procedures such as cardiac
catheterization are involved.18
Clinicians from other specialties may be aware of guidelines
but may still retain low-value practices from simple momentum
bias (we do not want to change unless a great reason is provided).16 There is evidence that pathologists need to review
data from their own institutions in order to show the potential
for harm associated with ordering the wrong test at the wrong
time or not ordering the right test at the right time.18,19 Data
about the ordering practices linked to actual outcomes can
address the optimism bias inherent in human nature that “more
is better” and that unconventional reasons for intervention will
improve care.18,19
The adoption of EMR and computerized order entry (CPOE)
have facilitated laboratory test ordering, data collection, and
analysis,20 as well as interventions to reduce necessary and
unnecessary testing.18,21-23 In theory, utilization management
has already become a target for inpatient clinical laboratory
services, as payment for laboratory testing has been reduced,
particularly in the inpatient setting. A systematic review of
publications between 1997 and 2012 identified more than 34
000 citations with medical subject headings for the combination of “utilization” and “laboratory test(s).” A discouraging
but not surprising finding was that a review of these studies
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using strict criteria found only 42 (0.1%) of them were welldone.24
The most common targets of utilization management are
unnecessary, redundant, or duplicative tests, whose elimination
could potentially reduce laboratory costs 16% to 20%.24,25
Underutilization of tests leading to delayed or missed diagnosis
is 2- to 3-fold (44%-45%) more common than overutilization
and likewise deserves intervention.24-26 In terms of health outcomes, underutilization is likely more important, yet it does not
have the same current national advocacy and that lack of parallel interest is problematic. One study in a critical discipline
(bleeding and thrombosis) found that underutilization of
laboratory tests resulted in only 55% of patients receiving
appropriate care.25 Difficult clinical scenarios are not the only
setting for serious underutilization. A minority of US patients
receive all their high-priority clinical preventive services,
including indicated laboratory tests.27
Changes to CPOE, including best practice alerts, have been
used to encourage orders of needed tests, to discourage duplicative and obsolete testing, and to prevent misordering of
“look-alike” tests.22,23,28 It is increasingly recognized that
CPOE changes alone achieve only a part of the needed
result29,30 and that a multimodal approach involving clinical
colleagues is often more effective.18,23,31-33 Other forms of
utilization management can involve removing tests from the
menu (in effect creating “test formularies”), requiring a pathologist review of specific tests, especially low-volume, high-cost
reference laboratory tests, and limiting some testing to expert
subspecialists.23,28
Test algorithms are increasingly used after the clinician
orders an initial test. Consistent use of laboratory recommended algorithms decreases costs significantly without concomitant decrease in quality; one large urban academic center
decreased inpatient test utilization and blood component utilization (often reimbursed in a bundled payment such as a diagnosis-related group (DRG)) by 26% for the average number of
tests per patient discharge and saved the hospital an estimated
$1.7 million per year over 10 years.23 Targeted tests have
included both rare and expensive genetics test, and common
and inexpensive tests such as basic metabolic profiles and
complete blood counts.29 The recent and important efforts of
the National “Choosing Wisely” campaign have put a welcome
emphasis on overutilization.34 Pathologists can take pride in
the cooperative approaches that have emphasized laboratory
testing in so many of the “Choosing Wisely” recommendations
for less intensive care. However, we should be concerned that
there is no parallel effort to address underutilization, especially
where it can improve targeted therapy.
An emerging literature suggests that utilization management
at the systems level is “the” important opportunity area for
pathology expertise.21 Pathologists must be prepared to participate in and/or lead this process as a routine part of practice,
particularly since inclusions of trainees in quality improvement
studies are an Accreditation Council for Graduate Medical
Education (ACGME) requirement for all residencies. While
downstream savings associated with systems interventions are
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likely to lead to the greatest value for society and the biggest
change in pathology practice,18,24,28 these savings have been
very difficult to quantify.18 Absent evidence, hospital administrators may not invest, federal and other insurers may not
recognize the work as having relative value, and funders of
research may continue to ignore the size, scope, and importance of the opportunity. As in every other investment that is
about the health of the public, the absence of evidence on the
value of utilization management threatens the role of pathology
and the overall performance of the health-care system. The
importance of pathologists becoming engaged in health services research to demonstrate the value of laboratory utilization
management cannot be overstated.

Precision Medicine
Expenditures for laboratory testing are projected to increase
disproportionately to other diagnostic costs, largely due to the
projected rise in genetic tests from $5 billion in 2010 to $15 to
25 billion in 2021.35 However, the anticipated problem of
increased costs for laboratory testing is small in comparison
to its downstream impact. Pathologists need to initiate and be
actively involved in evaluating the clinical utility of each new
test at the time it is proposed for introduction. Pathology expertise is essential to accurately assess the clinical benefit and
calculate the economic impact to determine true value. As an
example, there is little value in performing a more accurate
genetic test for cystic fibrosis in advance of performing a far
less expensive chloride sweat test as a screening test.36
Pathology trainees must be given the expectation that this
test assessment will be part of their job along with the educational experience to perform test assessment effectively. This
requires familiarity with record-keeping and analytics and the
ability to address issues such as the concordance of marketed
claims with actual test performance,37 the health-care impact
relative to the cost, and potential ethical conflicts related to the
introduction of new tests demanded by clinicians.
Extensive pathology involvement can help address current public skepticism about aspects of precision medicine.38 In particular, it is an opportunity to compare the
effectiveness of next-generation sequencing-based tests.39
The clinical utility of these tests is complicated by variations in data collected by different technical platforms and
the complexity of the data generated.37,39 In addition to
traditional evaluation of diagnostic and clinical validity,
more complex economic analyses may be necessary to provide justification for the costs of such tests.40
Despite these issues, there are many situations where the
significant clinical benefit and value of such tests justify their
current use. A good example is the successful evaluation of
companion diagnostics for targeted oncology therapies. 41
Although such testing can be quite expensive, the benefit is
that only patients with the targeted genetic mutation who are
likely to respond are treated with the even more expensive
targeted therapeutic, while those lacking the mutation would
receive futile and expensive care, with attendant risks for
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unnecessary adverse events.42-44 Another example is in the
diagnosis of infections, where rapid molecular testing provides
a quicker diagnosis compared to standard testing, therefore
improving patient outcomes by reducing mortality, morbidity,
hospital length of stay, and inappropriate antibiotic use.45,46
Molecular testing has also been applied effectively in anatomic
pathology; an example is in testing equivocal thyroid cytology
to better triage patients for surgery.47,48 An increasing number
of these and other new tests demonstrate clinical efficacy and
illustrate value for population health.49
Screening tests are another important area of growth. The
most well-known adjunct or replacement of a traditional
screening tool is the test for high-risk human papillomavirus.29,50-53 Many other tests are under development with
pathologists involved in creation of guidelines and algorithms.54 Molecular testing is increasingly used for noninvasive
prenatal screening.55 When pathologists and genetic counselors
work with clinicians to insure appropriateness of testing and
interpretation of results, the value is maximized.55-57 With
pathologist guidance in the preanalytic and postanalytic phases
of testing, molecular tests will improve timeliness of diagnosis,
reduce false negatives and false positives by defining the right
population with high pretest probability for the known performance of the test, and decrease downstream medical errors and
costs.

Reducing Diagnostic Errors
Measurement of error is an important step in identifying and
reducing errors, and the autopsy is the historical starting point
for identifying medical errors.58-60 This power to detect large
and small diagnostic error is known to persist in numerous
studies, despite increasingly sophisticated diagnostic techniques including imaging.61-67 Unfortunately, although the
value of the autopsy in detecting diagnostic errors is welldocumented, the autopsy rate continues to fall in both academic
and nonacademic hospitals.68,69
As autopsies for the sake of continuous quality improvement
and trainee learning diminish in frequency at many hospitals,
especially outside academic medical centers, a related concern
is that uncaught errors are not entered onto death certificates,
thus compromising their quality for subsequent mortality studies. Public health is degraded when error is missed and is
further degraded when summary data are compromised by the
absence of quality approaches. Surgical pathology diagnoses
also serve as feedback for medical errors to clinicians and those
in training. Pathologists reviewing surgical pathology cases can
detect trends for inappropriate management, collect and review
data, and intervene with clinical colleagues to improve patient
outcomes and reduce cost.19
But errors in the realm of laboratory medicine are more
pernicious and, perhaps, pervasive. Misutilization—the ordering of laboratory tests that are inappropriate for the clinical
questions being asked—is fostered by the ever-increasing number of available laboratory tests and the inability of busy physicians to stay abreast of their utility. 56,70-72 Indeed, a
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Figure 3. An updated view of the analytic process with steps to potentially reduce critical diagnostic errors.

resolution was recently passed by the House of Delegates of the
American Medical Association to close potential gaps in the
training of physicians in use and interpretation of laboratory
tests.73 The following case illustrates the seriousness of this
issue.

Clinical Scenario
A patient receives a laboratory test to diagnose a disease with a
population prevalence of 1%. The treatment for this disease
carries significant risk for morbidity due to side effects of the
therapy. The test is positive but actually a false-positive result.
The clinician, reading the test characteristics of 95% specificity
and 90% sensitivity, decides the test is very specific and treats
the patient with resulting complications.
Consider the outcomes for 1000 patients. A negative result
offers 99.9% probability that the patient does not have the
disease. The test in this situation is very useful for excluding
patients who do not have disease. However, a positive result
offers no such reassurance that the patient has the disease. The
chance of a patient having the disease given a positive test is
less than 20%, that is, if the laboratory test is used to make the
decision more than 5 patients without disease will be treated for
every patient with the disease. The lower the prevalence of a
disease, the more likely that a positive result is a false positive.
As prevalence rises, the positive predictive value rises and the
negative predictive value falls, so that a positive test result is
less helpful for a rare disease and a negative result is less helpful for a common disease. The inability of many physicians to
interpret tests correctly has drawn attention in the lay press.74

The addition of Bayesian pretest probability to laboratory testing is an operational way to think of the convergence of pathology and public health. In this scenario, some readers may
conclude that the test order is necessarily incorrect. That interpretation is neither implied nor precluded in this scenario; the
test may well be required in order to take the next step toward a
correct diagnosis. The correct message is that the clinical interpretation requires expertise informed by experience with test
performance and understanding of the population context.
Reducing diagnostic error, the subject of a recent National
Academy of Medicine (NAM) report, has become an important
goal for American medicine, as nearly all patients will experience a diagnostic error in their lifetime.58,75-77 Diagnostic error
is considered to be a failure of either the establishment of an
accurate and timely explanation for a patient’s health problems
and/or failure to accurately communicate this to the patient.58
The diagnostic process features complex steps in the preanalytic, analytic, and postanalytic phases, with each step providing
a chance for different types of critical errors (Figure 3). Reduction in true analytic errors is where pathologists have been most
engaged, and there remain ample opportunities to further
reduce analytic errors in quality control, sample identification,
and test interference.78 However, true analytic errors are estimated to be 10% of all errors in the diagnostic process as
regards laboratory testing.78 Pathologists must also work to
expand the footprint of quality oversight in the diagnostic process. As examples, anatomic pathology has actively improved
specimen identification using bar coding from specimen acquisition to sign-out, as well as encouraging second or consensus
opinions.79-81
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As mentioned earlier, most of the errors in clinical pathology occur in the preanalytic and postanalytic phases.78 When
clinicians do not order the correct tests (pre–pre analytic) or
misinterpret laboratory results (post–post analytic), misdiagnosis or delayed diagnosis are possible,82 which diminish the
quality of care and increase costs. The role of pathologists in
educating clinicians, guiding utilization, and interpreting
results will become even more critical, as the number and
complexity of tests continue to increase. Laposata and Cohen
(both members of the NAM committee) have advocated pathologist involvement in many areas to address medical errors,
such as increase the teaching of laboratory medicine in medical
school and beyond, optimize laboratory information systems
and improve the timely reporting of results, provide feedback
to clinicians on diagnostic errors and near-misses, and
acknowledge and learn from their own mistakes.83,84
There is substantial value for pathologists to become more
engaged in the interpretation and application of laboratory
tests, especially as consultants with clinical colleagues, educators of health providers, and investigators of diagnostic process
and errors. Each of these activities can add value to health-care
delivery by improving quality of care and reducing overall
costs. It is largely up to pathologists to make the case to receive
adequate and appropriate resources at the institutional and
national level to support these activities. Thus, pathologists
should be prepared to document the value of these efforts. As
laboratory testing is increasingly centralized and outsourced to
reference laboratory test results, a serious concern is the potential for a perceived lack of need for such activities by local
pathologists. The advantage that local pathologists have is
knowing the local patterns of utilization in their communities,
including opportunities for improvement and direct collaboration with local medical staff as part of the integrated provider
team. Several excellent examples of success have been demonstrated in both anatomic and clinical pathology. It is noteworthy that the NAM report made a major recommendation
to include pathologists as diagnostic experts, providing a firm
basis for pathologists to assume these roles as fully integrated
members of the diagnostic team.83 Finally, pathologists can
serve as educators for provider and patients in point-of-care
testing (POCT) such as glucose or international normalized
ratio (INR) testing for self-management of diabetes and
warfarin.

Improving Health-Care Outcomes
As noted earlier, the pathology “test” with the longest record
for improving safety and outcomes has been the autopsy. Following the dawn of modern Laboratory Medicine and Anatomic Pathology in the latter half of the 19th century, the
20th century saw the maturation of these disciplines as a foundational pillar of modern medicine, with discoveries through
experimental pathology to match. The challenge—and opportunity—for pathology and laboratory medicine in the 21st century is how the specialty will respond to the promise of
precision medicine and population health.

Academic Pathology
Fortunately, the clinical laboratory (inclusive of Anatomic
Pathology and the diagnostics of “Precision Medicine”) is ideally placed to help convert health care from “sick care” to
“wellness care.”10 Over the course of an individual’s lifetime,
clinical laboratory diagnostics inform the individual and her or
his health-care provider of their wellness status, their potential
risk for developing morbid conditions (acute or chronic), and
the actual advent of those conditions. To the extent that clinical
laboratories have comprehensive records on a regional population, it is precisely those laboratories that can provide leadership in empowering population health programming to serve
that region. In the simplest sense, laboratory professionals see
the diagnostic data first and are the subject matter experts in
test results interpretation and potential application.
In order to play this role, laboratory professionals (medical
and technical alike) need first to look at their own data. In the
transactional world of current medicine, the treating physician
orders the diagnostic testing, the clinical laboratory provides
the analytical results, those results are transmitted in atomized
fashion back to the treating physician and her or his clinical
care team, and patient management decisions are made on a
one-by-one basis. At the very least, and on behalf of individual
patients, the expertise and resources of the laboratory can be
harnessed through diagnostic management teams, as described
earlier. But to convert this expertise to the population level, the
laboratory must provide programmatic leadership. Termed
“Clinical Lab 2.0” by the Project Santa Fe Group,10 opportunities include but are not limited to
 reducing time to diagnosis and time to intervention;
 closing gaps in care, as through alerts, notifications,
improvements in patient access, and tracking of clinical
outcomes;
 powering wellness care screening, including triggering
early intervention;
 triggering real-time risk escalation and intervention;
 laboratory and pharmacy coordination, both for acute
conditions (such as antibiotic stewardship) and chronic
disease management; and
 building the evidence base for the efficacy and utility of
precision medicine, pharmacogenomics, and interventions instituted at the population level.
These population health leadership activities can play out in
both the inpatient and outpatient settings.85,86 Table 1 provides
examples of laboratory-led population health initiatives, which
have provided quantitative evidence of realized value in
improving patient outcomes and the cost of delivering health
care.87-92 For those individuals engaged in such projects, the
feeling is that we have only scratched the surface of what is
possible in this 21st century.
Informatics and emerging data sciences are critical to providing population health and precision medicine, and it is
imperative that laboratory leaders, who manage, understand,
and are the “first to see” the data, are actively engaged with
their clinical colleagues and administrators to make such
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Table 1. Laboratory-Led Population Health Initiatives.*
Health-Care Initiative

Outcomes

Pandemic infectious disease

Coordination with civic agencies for population management of influenza
outbreak
Improved clinical indices for diabetes control; decreased hospital admissions
Improved identification of contaminated blood cultures; decreased antibiotic
utilization
Earlier detection of community- and hospital-acquired in hospitalized patients
Decreased neonatal intensive care admissions; decreased total cost of care for
the child
Increased compliance with BCFV standards; increased detection of
bloodstream infection
Predicting social determinants of co-use and detecting geographic hotspots to
target educational initiatives

Workplace diabetes wellness
Antimicrobial stewardship
Acute kidney injury (AKI)
Prenatal care in diabetic mothers
Blood culture fill volume (BCFV)
Tracking co-use of
benzodiazepines and opioids

Publication Year Citation
2010

85

2014
2014

86

2018
2018

87

2019

89

2019

90

83

88

*Selected recent examples of population health initiatives with measurable, quantitative outcomes that were led by clinical laboratory personnel, in coordination
with a broad constituency of medical, institutional, and on occasion, commercial insurer and civic agency stakeholders.

information actionable. The first priority should be addressing
the needs of stakeholders:
 Patients: Laboratory data analytics are essential components of clinical care management programs designed to
improve safety and meet the needs of patients individually (precision medicine) and regionally (population
health). In addition, most patients frequently access
EMR laboratory results in advance of visits with their
providers. Pathologists should explore the opportunity
of using this “patient interface” to directly engage
patients and improve population health.
 Clinical providers: Laboratory data are necessary to
develop evidence-based decision support tools to
improve clinical practice efficiency and precision,
reduce medical errors, manage potential gaps in patient
care, and improve interpretation of laboratory testing.
 Institutional quality: Laboratory data inform a substantial portion of institutional performance metrics, including gaps in care, cost-effectiveness, care coordination,
and appropriate benchmark comparisons.93-95
 Institutional finance: Payment systems, especially those
that are value-based, are driven by quality metric ratings
across inpatient and ambulatory settings.96 Laboratory
data are also key for “risk-adjusting” patients who are
members of managed care plans; failure to properly risk
adjust these patients can have strong negative impact on
financial outcomes.97
 Payers: Beyond the obligate linkage of data to inform
actuarial analysis and design of health-care plans, the
quality and financial metrics mentioned earlier are key
mechanisms by which payers assess the quality of health
care being delivered to their members (patients).
 Benefits design: Laboratory data initiatives will become
increasingly important in Benefits Design and Benefits
Coverage for managed care and value-based health
plans. The recent National Coverage Decision by the
Centers for Medicaid and Medicare Services (CMS)

approved a major molecular diagnostic laboratory for
Medicare coverage, simultaneous with FDA approval
of their test offering.98 This joint ruling by CMS and
FDA was based on a process which should be kept in
mind by other laboratories seeking to obtain laboratory
testing coverage approvals by payers.

Discussion
We have described 4 major initiative areas that are critical to
population health in which pathologists have the opportunity to
provide significant additional value and a leadership role, but
only to the extent and speed that the pathology community is
willing and able to engage. Pharmacists have markedly
improved safety and efficacy by actively participating in clinical rounds, demonstrating the importance of active engagement that should be a model for pathologists.99-101
A major constraint to all these initiatives is the lack of
dedicated funding for the considerable amount of pathologist
and informatics effort that must go into population health
initiatives, even though they improve quality and reduce costs
disproportionately to needed investment.102 Unfortunately,
reimbursement policies for tests can drive inappropriate
utilization from both directions (ie, overutilization in a feefor-service model and underutilization in a capitated model).
However, as pointed out earlier, the test is not the important
cost; the downstream costs are what matter most. Test costs
should be tied to processes that put a premium on getting the
most appropriate test at the right time for the right patient and
assuring timely action on these results.
Investments in accurate ordering and interpretation have
been limited predominantly to academic centers102 and large
integrated systems with accompanying investments in clinical
pathways and outcomes. The greatest returns in value for the
cost of tests are in the processes that improve patient outcomes
and reduced total cost of care. Pathologists are the most knowledgeable professionals in this arena and should become more

8
actively engaged in educating payers and hospital administrators that the incremental costs for improving safety and utilization are small in comparison to potential savings from more
efficient total cost of care.23 83
In addition, pathologists should work with clinical colleagues, health system leaders, patient advocates, and professional societies to educate federal agencies such as Centers for
Medicare and Medicaid Services (CMS), National Institutes of
Health (NIH), Centers for Disease Control and Prevention
(CDC), Food and Drug Administration (FDA), Patient-Centered
Outcomes Research Institute (PCORI), and Agency for Healthcare Research and Quality (AHRQ) to fund demonstration projects and studies addressing safety and best practices for test
utilization. Pathologists should also seek to work directly with
payers to achieve alignment in managed care program design
and execution. Unfortunately, pathologists have not engaged
effectively with these stakeholders, and not surprisingly, these
federal agencies have provided inadequate funding for studying
the important impact of test quality and utilization on reducing
diagnostic errors and improving quality.83 Moreover, the number of US pathologists has decreased significantly in both absolute (17.5%; 15 568-12 839) and population-adjusted
(23.6%; 5.16-3.94 per 100 000) totals from 2007 to 2017.76
This alarming trend has diminished the ability of pathology and
pathologists to help advance population health and precision
medicine and limited their contributions to the research and
education needed to realize these goals.77
Pathologists have broad expertise that impacts the care of
patients across all specialties, which qualify them to be
“systems-level” consultants. Some pathologists have acquired
the skills to leverage this expertise to become valued members
of the leadership teams of health-care organizations but more
need to assume these roles to help the profession and the
patients being served. Pathology training also should reflect
these opportunities and the value that our profession can bring
to health care, important for attracting a new generation of
pathologists. Training should include a focus on data science,
drawing on the rich data sources emanating from pathology and
the clinical laboratory. Although pathologists already have
considerable training in the statistical methods used to validate
our analytic processes and in systems thinking as well as operations approaches required to direct our laboratories, most
pathologists report that they would benefit from more statistics
training.103 Training in health systems science should be provided to show how the skills and knowledge of pathologists can
be applied to designing and potentially leading programs to
improve health-care delivery. Likewise, basic principles of
public health should be provided, especially in epidemiology,
as it relates to the correlation of test utilization with population
health. Enhanced training in communication and negotiation
will also be important for pathologists to become more engaged
with practicing in clinical teams, dealing with administrators
and payers, and educating stakeholders.
The next generation of pathologists must be able to recognize
and seek rigorous study design for comparative effectiveness,
manage and utilize summary data for error reduction studies and
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control of ordering, introduce alterations to medical records that
guide or steer clinicians to the right test, and communicate the
need to change and the consequences of current trends. Pathology training programs should reach out to other specialties to
train in the laboratory as well as send pathology house staff on
rounds to improve test ordering and management using laboratory test results.104 An understanding of health economics will
also be required, as pathologists help to determine which methods are cost- as well as clinically effective. Training should
likewise emphasize dissemination and implementation sciences
(knowledge translation or knowledge diffusion). Pathology leadership of diagnostic teams, visible beyond the walls of the
laboratory, armed with data, and facilitating changes in the
wards, the emergency department, and the C-suite, will attract
the best and brightest of medical students to the field.
With payers moving to value-based models of compensation, traditional Part B billing and reimbursement is at risk.105
While pathologists will continue to perform direct patient care
services such as signing out surgical pathology specimens, the
inexorable move toward value-based reimbursement will likely
reduce payment for these services, which currently constitute a
major portion of practice revenue. As laboratory test reimbursement likewise shrinks, the hospital or academic laboratory
itself is at risk, which implies that Part A payments also will be
at risk.10,106 The challenge for pathologists will be not only to
add value but to also quantitatively prove to payers and health
systems of the value we have added and of their return on
investment for supporting pathologists in these new activities.

Conclusion
The shift from fee-for-service to value-based payment and the
implementation of population health and precision medicine
are strong incentives for pathologists to focus on the value they
can bring to patient care. For the profession to thrive, pathologists must focus on extending their role beyond the laboratory.
Pathologists must become critical members of the health-care
provider team as physicians and consultants, with leadership
responsibility for correlating laboratory testing to patient outcomes and error prevention. Pathologists must leverage their
skills and experience to improve quality and cost-effectiveness.
Pathologists must train a new generation of pathologists who
understand the role of pathology in value-based care and precision medicine. Pathologists must engage in health services
research to generate the evidence that supports their value in
health-care delivery. Pathologists must proactively engage in
educating other stakeholders, both within and outside the
health-care delivery system, on the value they bring to population health. Alternatively, if pathologists are unable or
unwilling to take advantage of these challenges and opportunities, pathology likely will be viewed as a cost and liability
and will diminish as a profession.
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